WO2005002625A3 - In-situ gelling drug delivery system - Google Patents

In-situ gelling drug delivery system Download PDF

Info

Publication number
WO2005002625A3
WO2005002625A3 PCT/US2004/020369 US2004020369W WO2005002625A3 WO 2005002625 A3 WO2005002625 A3 WO 2005002625A3 US 2004020369 W US2004020369 W US 2004020369W WO 2005002625 A3 WO2005002625 A3 WO 2005002625A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
delivery system
situ gelling
gel
gelling drug
Prior art date
Application number
PCT/US2004/020369
Other languages
French (fr)
Other versions
WO2005002625A2 (en
Inventor
Paul Ashton
Jianbing Chen
Dongling Su
Original Assignee
Control Delivery Sys Inc
Paul Ashton
Jianbing Chen
Dongling Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Sys Inc, Paul Ashton, Jianbing Chen, Dongling Su filed Critical Control Delivery Sys Inc
Priority to PL04756068T priority Critical patent/PL1635875T3/en
Priority to EP04756068A priority patent/EP1635875B8/en
Priority to JP2006517646A priority patent/JP5229768B2/en
Priority to CN2004800237331A priority patent/CN1863557B/en
Priority to SI200430994T priority patent/SI1635875T1/en
Priority to DK04756068T priority patent/DK1635875T3/en
Priority to CA2530136A priority patent/CA2530136C/en
Priority to DE602004016995T priority patent/DE602004016995D1/en
Publication of WO2005002625A2 publication Critical patent/WO2005002625A2/en
Publication of WO2005002625A3 publication Critical patent/WO2005002625A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.
PCT/US2004/020369 2003-06-26 2004-06-25 In-situ gelling drug delivery system WO2005002625A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL04756068T PL1635875T3 (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system
EP04756068A EP1635875B8 (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system
JP2006517646A JP5229768B2 (en) 2003-06-26 2004-06-25 In-situ gelled drug delivery system
CN2004800237331A CN1863557B (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system
SI200430994T SI1635875T1 (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system
DK04756068T DK1635875T3 (en) 2003-06-26 2004-06-25 In-situ gelling drug administration system
CA2530136A CA2530136C (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system
DE602004016995T DE602004016995D1 (en) 2003-06-26 2004-06-25 IN-SITU GELIEREN MEDZIMITTELABGABESYSTEM

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48267703P 2003-06-26 2003-06-26
US60/482,677 2003-06-26
US57530704P 2004-05-28 2004-05-28
US60/575,307 2004-05-28

Publications (2)

Publication Number Publication Date
WO2005002625A2 WO2005002625A2 (en) 2005-01-13
WO2005002625A3 true WO2005002625A3 (en) 2005-04-21

Family

ID=33567657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020369 WO2005002625A2 (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system

Country Status (16)

Country Link
US (4) US20050048123A1 (en)
EP (2) EP2044959A1 (en)
JP (1) JP5229768B2 (en)
CN (2) CN101862455A (en)
AR (1) AR044926A1 (en)
AT (1) ATE410186T1 (en)
CA (1) CA2530136C (en)
CY (1) CY1108685T1 (en)
DE (1) DE602004016995D1 (en)
DK (1) DK1635875T3 (en)
ES (1) ES2315680T3 (en)
PL (1) PL1635875T3 (en)
PT (1) PT1635875E (en)
SI (1) SI1635875T1 (en)
TW (1) TWI377958B (en)
WO (1) WO2005002625A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
ES2428354T3 (en) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamycin for use in the inhibition or prevention of choroidal neovascularization
CN102144961A (en) * 2003-09-18 2011-08-10 参天制药株式会社 Transscleral delivery
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP5528708B2 (en) 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
JP4827626B2 (en) * 2006-06-14 2011-11-30 キヤノン株式会社 CONTROLLED DEVICE, REMOTE CONTROL SYSTEM, REMOTE CONTROL SYSTEM CONTROL METHOD, PROGRAM
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
MX337286B (en) 2007-05-25 2016-02-22 Indivior Uk Ltd Sustained delivery formulations of risperidone compounds.
WO2009120358A1 (en) * 2008-03-27 2009-10-01 Nektar Therapeutics Oligomer-nitrogenous base conjugates
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
WO2009129148A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Methods and compositions for treating intervertebral disc herniations
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB201014591D0 (en) * 2010-09-02 2010-10-13 Univ Nottingham Compositions
EA026964B1 (en) * 2010-11-24 2017-06-30 Дьюрект Корпорейшн Biodegradable drug delivery composition (embodiments)
US20140271861A1 (en) * 2011-07-27 2014-09-18 Polypid Ltd. Matrix compositions for controlled release of peptide and polypeptide molecules
CA2901280A1 (en) * 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
WO2016100392A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
KR20180054627A (en) 2015-09-21 2018-05-24 테바 파마슈티컬스 인터내셔널 게엠베하 Sustained-release olanzapine preparation
TWI641387B (en) * 2015-10-29 2018-11-21 逸達生物科技股份有限公司 Pharmaceutical composition with improved stability
MX2018005932A (en) 2015-11-12 2019-05-20 Graybug Vision Inc Aggregating microparticles for therapy.
WO2018169934A1 (en) * 2017-03-14 2018-09-20 The Children's Hospital Of Philadelphia Cleavable esters for nanocarrier-based cancer therapy
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
BR112019019452A2 (en) 2017-03-23 2020-04-14 Graybug Vision Inc compound, and, use of a compound
RU2019139817A (en) 2017-05-10 2021-06-10 Грейбуг Вижн, Инк. DELAYED RELEASE MICROPARTICLES AND THEIR SUSPENSIONS FOR DRUG THERAPY
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
AU2018285975B2 (en) * 2017-06-13 2023-11-16 The University Of British Columbia Polymeric paste compositions for drug delivery
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
UY38386A (en) * 2018-09-25 2020-04-30 Tolmar Int Ltd LIQUID POLYMER DELIVERY SYSTEM FOR PROLONGED ADMINISTRATION OF DRUGS
CN111374940A (en) * 2020-04-13 2020-07-07 宁波赛缪斯生物科技有限公司 Collagen injection capable of in-situ polymerization and use method thereof
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026015A1 (en) * 1996-01-16 1997-07-24 Delab Sustained release drug formulations
WO2002000137A1 (en) * 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
WO2002036169A2 (en) * 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
WO2002045689A1 (en) * 2000-12-07 2002-06-13 Samyang Corporation Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20030082234A1 (en) * 1999-12-22 2003-05-01 Min-Hyo Seo Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
JPS59110607A (en) 1982-12-17 1984-06-26 シ−トン・カンパニ− Soft continuous film for medical cosmetics
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
AU3432689A (en) 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5681964A (en) 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
JPH07502507A (en) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド Method for treating osteoporosis using bisphosphonates and parathyroid hormone
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
JP4259610B2 (en) * 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド Liquid delivery composition
GB9409281D0 (en) 1994-05-10 1994-06-29 Svedman Paul Transdermal device
US5607686A (en) 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
DE19607395C2 (en) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salts from a cationic narcotic analgesic with an anionic non-narcotic analgesic, process for their preparation and the pharmaceutical preparations containing these salts
ES2158611T3 (en) 1996-12-20 2001-09-01 Alza Corp COMPOSITION IN INJECTABLE GEL WITH RETARD EFFECT AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION.
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
JP2002532406A (en) 1998-12-17 2002-10-02 アルザ・コーポレーション Conversion of liquid-filled gelatin capsules into controlled-release systems with composite coatings
JP2003501375A (en) 1999-06-04 2003-01-14 アルザ・コーポレーション Implantable gel composition and method of manufacture
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
CN1206001C (en) * 2000-06-28 2005-06-15 A·J·舒克拉 Biodegradable carrier and biodegradable transfer system
WO2002087586A1 (en) 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
RS55578B1 (en) 2002-01-18 2017-06-30 Biogen Ma Inc Polyalkylene polymer compounds and uses thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
JP5305135B2 (en) 2008-08-05 2013-10-02 株式会社リコー Lubricant thinning device, and image forming apparatus and process cartridge provided with the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026015A1 (en) * 1996-01-16 1997-07-24 Delab Sustained release drug formulations
US20030082234A1 (en) * 1999-12-22 2003-05-01 Min-Hyo Seo Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
WO2002000137A1 (en) * 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
WO2002036169A2 (en) * 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
WO2002045689A1 (en) * 2000-12-07 2002-06-13 Samyang Corporation Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAIN R A ET AL: "CONTROLLED DELIVERY OF DRUGS FROM A NOVEL INJECTABLE IN SITU FORMED BIODEGRADABLE PLGA MICROSPHERE SYSTEM", JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS INC. LONDON, GB, vol. 17, no. 3, May 2000 (2000-05-01), pages 343 - 362, XP000912452, ISSN: 0265-2048 *

Also Published As

Publication number Publication date
US20050048123A1 (en) 2005-03-03
EP1635875B8 (en) 2008-12-24
EP1635875B1 (en) 2008-10-08
CN101862455A (en) 2010-10-20
DE602004016995D1 (en) 2008-11-20
TWI377958B (en) 2012-12-01
EP2044959A1 (en) 2009-04-08
DK1635875T3 (en) 2009-01-12
CN1863557A (en) 2006-11-15
CY1108685T1 (en) 2014-04-09
US20140336278A1 (en) 2014-11-13
US9566336B2 (en) 2017-02-14
AR044926A1 (en) 2005-10-12
CA2530136C (en) 2012-10-16
SI1635875T1 (en) 2009-04-30
EP1635875A2 (en) 2006-03-22
WO2005002625A2 (en) 2005-01-13
US20110165242A1 (en) 2011-07-07
PT1635875E (en) 2008-12-09
ATE410186T1 (en) 2008-10-15
US20130101656A1 (en) 2013-04-25
PL1635875T3 (en) 2009-03-31
ES2315680T3 (en) 2009-04-01
CN1863557B (en) 2010-06-16
TW200514581A (en) 2005-05-01
JP2007524628A (en) 2007-08-30
JP5229768B2 (en) 2013-07-03
CA2530136A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
WO2005002625A3 (en) In-situ gelling drug delivery system
CA2395077A1 (en) Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
WO2004052336A3 (en) High viscosity liquid controlled delivery system and medical or surgical device
WO2005055979A3 (en) Ph triggerable polymeric particles or films containing a poly (beta-amino ester)
WO2006065951A3 (en) Sustained delivery formulations of octreotide compounds
WO2004056311A3 (en) Stimuli-responsive systems for controlled drug delivery
WO2007133389A3 (en) Apparatus and method for delivery of therapeutic and other types of agents
WO2005034859A3 (en) Extended release formulations of opioids and method of use thereof
WO2005023176A3 (en) Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides
PT774964E (en) CONTROLLED LOCAL DELIVERY OF CHEMOTHERAPEUTIC AGENTS FOR TREATMENT OF SOLID TUMORS
DE69721481D1 (en) DELAYED RELEASE ACTIVE SUBSTANCE FORMULATIONS
DE69938552D1 (en) INJECTION MOLDABLE FIXED ADMINISTRATION SYSTEMS
IL223488A (en) Injectable flowable composition comprising buprenorphine
WO2007016622A3 (en) Gel composition for inhibiting cellular adhesion
WO1995024430A3 (en) Block and graft copolymers and methods relating thereto
UY25936A1 (en) DELAYED DRUG FORMULATIONS CONTAINING A COMBINATION OF AN OPIOID AND ALPHA-AGONIST
AU2273302A (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
WO2005009408A3 (en) Sustained release dosage forms of anesthetics for pain management
DE60023520D1 (en) LIQUID HIGH VISIBLE SYSTEM WITH CONTROLLED RELEASE AND MEDICAL OR SURGICAL DEVICE
WO2004043432A3 (en) Controlled release depot formulations
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
BRPI0514293A (en) diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug administration
WO2004112748A3 (en) Rate controlled release of a pharmaceutical agent in a biodegradable device
BRPI0416590A (en) excipients in drug delivery vehicles
WO2006041942A3 (en) Ocular delivery of polymeric delivery formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480023733.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2530136

Country of ref document: CA

Ref document number: 2006517646

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004756068

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 163/DELNP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004756068

Country of ref document: EP